Multiple potency of ezetimibe in a patient with macroproteinuric chronic kidney disease and statin-intolerant dyslipidemia

We report that ezetimibe monotherapy for 12months improved lipid profiles in a patient with CKD and statin-intolerant dyslipidemia. Ezetimibe also reduced proteinuria and urinary liver-type fatty acid binding protein levels, improved endothelial function, and decreased carotid atherosclerosis. These findings suggest that ezetimibe monotherapy may have beneficial multipotent effects on renal/vascular function.>
Source: Journal of Cardiology Cases - Category: Cardiology Source Type: research